Country

Effective Date

Description of action taken
Grounds for decision

United Kingdom

1999

The licence for the antidepressant, trancylopramine and trifluorperazine has not been renewed by the Committee on Safety of Medicines because of concerns over drug interactions and the risk of severe hypertensive crises. As a result the company have withdrawn the product from the market. (Reference: Current Problems in Pharmacovigilance Vol. 25, June 1999.)